Corporate Milestones
2023
Establishment of BioKey Cayman, Inc. as a Cayman-incorporated SEC-reporting life sciences corporation.
May 2025
Strategic corporate reorganization and acquisition of 100% equity in BioKey, Inc. from ABVC BioPharma.
June 2026
Effective Form 10 filing and official registration of the corporate structure with the SEC.
August 2026
Anticipated spin-off distribution of equity to ABVC shareholders, marking a significant corporate milestone.
Corporate Evolution
Since its Cayman incorporation in 2023, BioKey has established a robust operational foundation. In May 2025, the company completed a strategic reorganization by acquiring 100% equity in BioKey, Inc., a California-based pharmaceutical CDMO. This transition is set to be formally recognized through a Form 10 filing in June 2026, marking a significant milestone in our institutional development and life sciences platform.
